191 related articles for article (PubMed ID: 37760587)
21. [Comparison of Therapeutic Efficacy between Hypomenthylating Agents Combined with Venetoclax and Half Dose Priming Regimen in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia].
Xu MZ; Qiao M; Sun AN; Wu DP; Xue SL; Zhou HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1631-1636. PubMed ID: 36476881
[TBL] [Abstract][Full Text] [Related]
22. Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia.
Arora S; Zainaldin C; Bathini S; Gupta U; Worth S; Bachiashvili K; Bhatia R; Godby K; Jamy O; Rangaraju S; Diamond B; Oliver JD; Salzman D; Di Stasi A; Vachhani P
Leuk Res; 2022 Jun; 117():106844. PubMed ID: 35487134
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective.
Pratz KW; Chai X; Xie J; Yin L; Nie X; Montez M; Iantuono E; Downs L; Ma E
Pharmacoeconomics; 2022 Aug; 40(8):777-790. PubMed ID: 35696071
[TBL] [Abstract][Full Text] [Related]
24. Fix low dose venetoclax-azacitidine treatment of unfit acute myeloid leukemia patients.
Miklos E; Oliver TP; Adam K; Eva K; Balazs K; Eszter K; Anett P; Viktoria GK; Jozsef H; Peter R
Eur J Haematol; 2024 Apr; ():. PubMed ID: 38644361
[TBL] [Abstract][Full Text] [Related]
25. A real-world experience of venetoclax combined with hypomethylating agents vs. monotherapy hypomethylating agents in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia patients.
Zhang L; Ge R; Pan D; Yue P; Zhang J; Bian R; Yan X
Front Pharmacol; 2024; 15():1265840. PubMed ID: 38756378
[TBL] [Abstract][Full Text] [Related]
26. Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan.
Asada N; Ando J; Takada S; Yoshida C; Usuki K; Shinagawa A; Ishizawa K; Miyamoto T; Iida H; Dobashi N; Okubo S; Honda H; Soshin T; Nishimura Y; Tsutsui A; Mukai H; Yamamoto K
Jpn J Clin Oncol; 2023 Jun; 53(7):595-603. PubMed ID: 37017320
[TBL] [Abstract][Full Text] [Related]
27. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
28. The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis.
Liu B; Guo Y; Deng L; Qiao Y; Jian J
Hematology; 2020 Dec; 25(1):414-423. PubMed ID: 33191860
[TBL] [Abstract][Full Text] [Related]
29. Advancing the standard: venetoclax combined with intensive induction and consolidation therapy for acute myeloid leukemia.
Lachowiez CA; Atluri H; DiNardo CD
Ther Adv Hematol; 2022; 13():20406207221093964. PubMed ID: 35510212
[TBL] [Abstract][Full Text] [Related]
30. Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US.
Vachhani P; Flahavan EM; Xu T; Ma E; Montez M; Gershon A; Onishi M; Jin H; Ku G; Flores B; Bui CN; Abbas JA; Donnellan W
Oncologist; 2022 Nov; 27(11):907-918. PubMed ID: 35925602
[TBL] [Abstract][Full Text] [Related]
31. Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases.
Wang N; He J; Liu F
Chemotherapy; 2022; 67(3):178-182. PubMed ID: 35306492
[TBL] [Abstract][Full Text] [Related]
32. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia.
Cherry EM; Abbott D; Amaya M; McMahon C; Schwartz M; Rosser J; Sato A; Schowinsky J; Inguva A; Minhajuddin M; Pei S; Stevens B; Winters A; Jordan CT; Smith C; Gutman JA; Pollyea DA
Blood Adv; 2021 Dec; 5(24):5565-5573. PubMed ID: 34610123
[TBL] [Abstract][Full Text] [Related]
33. Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients.
Shimony S; Garcia JS; Keating J; Chen EC; Luskin MR; Stahl M; Neuberg DS; DeAngelo DJ; Stone RM; Lindsley RC
Leukemia; 2024 Mar; ():. PubMed ID: 38538860
[TBL] [Abstract][Full Text] [Related]
34. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
[No Abstract] [Full Text] [Related]
35. Intensive Induction Chemotherapy versus Hypomethylating Agents in Combination with Venetoclax in NPM1-mutant AML.
Bewersdorf JP; Shimony S; Shallis RM; Liu Y; Berton G; Schaefer EJ; Zeidan AM; Goldberg AD; Stein EM; Marcucci G; Bystrom R; Lindsley RC; Chen EC; Ramos Perez JM; Stein AS; Pullarkat VA; Aldoss I; DeAngelo DJ; Neuberg DS; Stone RM; Garciaz S; Ball BJ; Stahl M
Blood Adv; 2024 Jun; ():. PubMed ID: 38941537
[TBL] [Abstract][Full Text] [Related]
36. Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia.
Othman TA; Azenkot T; Moskoff BN; Tenold ME; Jonas BA
Future Oncol; 2021 Aug; 17(23):2989-3005. PubMed ID: 34024158
[TBL] [Abstract][Full Text] [Related]
37. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.
Maiti A; DiNardo CD; Qiao W; Kadia TM; Jabbour EJ; Rausch CR; Daver NG; Short NJ; Borthakur G; Pemmaraju N; Yilmaz M; Alvarado Y; Montalbano KS; Wade A; Maduike RE; Guerrero JA; Vaughan K; Bivins CA; Pierce S; Ning J; Ravandi F; Kantarjian HM; Konopleva MY
Cancer; 2021 Nov; 127(22):4213-4220. PubMed ID: 34343352
[TBL] [Abstract][Full Text] [Related]
38. Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.
Heuser M; Fernandez C; Hauch O; Klibanov OM; Chaudhary T; Rives V
Future Oncol; 2023 Apr; 19(11):789-810. PubMed ID: 37170899
[TBL] [Abstract][Full Text] [Related]
39. The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions.
Piccini M; Mannelli F; Coltro G
Bioengineering (Basel); 2023 May; 10(5):. PubMed ID: 37237661
[TBL] [Abstract][Full Text] [Related]
40. Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia.
Weng G; Zhang Y; Yu G; Luo T; Yu S; Xu N; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Shao R; Du X; Jin H; Liu Q
J Intern Med; 2023 Mar; 293(3):329-339. PubMed ID: 36284445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
